AstraZeneca (AZN LN) - Q4 (USD): Core EPS 2.12 (exp. 2.14), Revenue 15.5bln (exp. 15.46bln), guides initial FY26 revenue up by mid-to-high single digit and core EPS up by double-digit percentage

AstraZeneca's Q4 results slightly missed expectations on core EPS and revenue, indicating potential short-term pressure on the stock.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Barclays (BARC LN) Q4 (GBP) Revenue 7.08bln (prev. 6.96bln Y/Y), PBT 1.86bln (exp. 1.76bln); announces share buyback of GBP 1bln

Additional European Equity News

AstraZeneca (AZN LN) - Q4 (USD): Core EPS 2.12 (exp. 2.14), Revenue 15.5bln (exp. 15.46bln), guides initial FY26 revenue up by mid-to-high single digit and core EPS up by double-digit percentage

Newsquawk Daily European Equity Opening News - 10th February 2026

India is reportedly in talks with France, Netherlands, Brazil and Canada over a deal on critical minerals

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Q4 Imfinzi revenue USD 1.75bln (exp. 1.61bln).
  • FY25 oncology revenue USD 25.62bln (prev. 7.03bln Y/Y)
  • Co. gets CDSCO approval for Durvalumab in India.
Context

However, the guidance for FY26 shows confidence with a mid-to-high single-digit revenue increase and a double-digit percentage growth in core EPS, which suggests management's optimism about future performance. This divergence may create mixed sentiment in the market, with a focus on longer-term growth prospects over the immediate miss.

Related headlines

The whole workspace, free to try.

Try it free